The risks of investing in AbbVie Inc. (ABBV)

From the Sep 26, 2026 report · Read the full report

Risks flagged in the analysis

Patent cliff risks from Imbruvica decline, mitigated by new oncology therapies.
Inflation-driven cost increases (CPI +3.05%) may squeeze margins.
Competitive pressure from Eli Lilly (LLY) with 49.6% revenue growth.

Bear case

Negative equity (Common Stock Equity: -$5.93B) and negative working capital (-$7.97B).
Current ratio of 0.81 (below 1.0) signals potential short-term liquidity pressure.
TTM PE of 74.46 is historically high due to temporary earnings headwinds.

Risk in numbers

Beta: 0.28
Annual volatility: 26.3%
Largest fall in 12 months: -19.2%

52-week range

$190.75$269.39

Frequently asked questions

What are the risks of investing in ABBV?

Patent cliff risks from Imbruvica decline, mitigated by new oncology therapies. Inflation-driven cost increases (CPI +3.05%) may squeeze margins. Competitive pressure from Eli Lilly (LLY) with 49.6% revenue growth.

Sources: Yahoo Finance (prices, financial statements and analysts' estimates) and the U.S. Treasury (10-year yield). Indicators and valuation are computed without AI.

AI-generated informational content. Not financial advice or a personalised investment recommendation. Investing involves risk, including loss of capital.

Every week, in your inbox

Rating changes, the highest-conviction stocks and the week's best research. Free.